Why is Astec Lifescienc falling/rising?

As of 07-Nov, Astec Lifesciences Ltd is experiencing a decline in its stock price, currently at Rs 634.95, reflecting a decrease of Rs 8.1 or 1.26%. The stock has hit a new 52-week low of Rs 616.9 today and has underperformed its sector by 1.66%. Over the last three days, the stock has consistently fallen, resulting in a total decline of 5.41%. The company has reported negative results for the last six consecutive quarters, with operating cash flow at its lowest and a high debt-to-EBITDA ratio of 9.40 times, indicating significant financial strain. Additionally, the stock has underperformed against the benchmark indices, with a staggering 41.30% decline over the past year, further highlighting its weak long-term fundamental strength.
In the broader market context, the stock's performance over the past week shows a decline of 3.77%, while the Sensex has only decreased by 0.86%. This stark contrast underscores the stock's consistent underperformance, particularly over the last three years, where it has lagged behind the benchmark in each annual period. The liquidity of the stock remains adequate for trading, but the falling investor participation, evidenced by a 48.78% drop in delivery volume, suggests a lack of confidence among investors. Overall, the combination of poor financial results, high debt levels, and significant underperformance relative to the market contributes to the stock's downward trajectory.